Voglibose
As of the edition of 20 October 2026, Voglibose is a small molecule: marketed, first approved in 2011 (JP); acts on GAA, MGAM and MGAM2 and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2011
- Kind
- Small molecule
- Brand name
- Glubes
- First approved
- 22 April 2011 (JP)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- Kissei Pharmaceutical; 2 holders in all
- Registered trials
- 9, 0 stopped early
- Disease areas
- Nutrition and metabolism; Hormones; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 3 | 4 | 3 | 0 | 0 |
| Phase 4 | 3 | 3 | 0 | 0 |
| All trials | 9 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Takeda | Later holder and Lead sponsor of trials | 2007 to now |
| Kissei Pharmaceutical | Applicant | 2011 to now |